GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Debt-to-EBITDA

Resverlogix (TSX:RVX) Debt-to-EBITDA : 0.82 (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resverlogix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$9.20 Mil. Resverlogix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Resverlogix's annualized EBITDA for the quarter that ended in Mar. 2024 was C$11.21 Mil. Resverlogix's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.82.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Resverlogix's Debt-to-EBITDA or its related term are showing as below:

TSX:RVX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.81   Med: -0.43   Max: 1.87
Current: -0.92

During the past 13 years, the highest Debt-to-EBITDA Ratio of Resverlogix was 1.87. The lowest was -6.81. And the median was -0.43.

TSX:RVX's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.34 vs TSX:RVX: -0.92

Resverlogix Debt-to-EBITDA Historical Data

The historical data trend for Resverlogix's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Debt-to-EBITDA Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.39 0.11 -0.31 -6.81 -0.48

Resverlogix Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.52 -0.45 -0.69 0.82

Competitive Comparison of Resverlogix's Debt-to-EBITDA

For the Biotechnology subindustry, Resverlogix's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Resverlogix's Debt-to-EBITDA falls into.



Resverlogix Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Resverlogix's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.056 + 0) / -19.024
=-0.48

Resverlogix's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.195 + 0) / 11.212
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Resverlogix  (TSX:RVX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Resverlogix Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Resverlogix's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix (TSX:RVX) Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines